Pulmatrix

Yahoo Finance • 2 months ago

Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction

Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader antibody conjugate therapies... Full story